Last reviewed · How we verify
brinzolamide 1% ophthalmic suspension
Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye.
Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye. Used for Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma, Secondary open-angle glaucoma.
At a glance
| Generic name | brinzolamide 1% ophthalmic suspension |
|---|---|
| Also known as | AZOPT®, AZOPT™, brinzolamide |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting carbonic anhydrase, brinzolamide decreases the production of aqueous humor, thereby reducing intraocular pressure. This is particularly useful in the treatment of glaucoma and ocular hypertension.
Approved indications
- Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma
- Secondary open-angle glaucoma
Common side effects
- Headache
- Diplopia
- Fatigue
- Nausea
- Eye pain
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections (NA)
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: